Clinical Trial Update: A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the effectiveness and safety of solifenacin succinate suspension for treating overactive bladder in children aged 5 to under 18, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Solifenacin succinate suspension (Solifenacin succinate)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED | Results posted: 2017-01-30